Autogene cevumeran Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Autogene cevumeran Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Autogene cevumeran can convert its Personalized antigen vaccine, mRNA vaccine profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Autogene cevumeran (query alias: Autogene cevumeran) |
|---|---|
| Modality / target | Personalized antigen vaccine, mRNA vaccine; Not disclosed; Immunostimulants |
| Highest global status | Phase 2 |
| Originator | BioNTech SE |
| Active developers | Genentech, Inc., Memorial Sloan Kettering Cancer Center, BioNTech SE |
The MCP disease footprint includes Muscle Invasive Bladder Urothelial Carcinoma, Pancreatic Ductal Adenocarcinoma, Unresectable Acral Lentiginous Melanoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06534983 | Phase 2 | Terminated | 62 | Primary endpoint not disclosed in English source |
| CTIS2023-509023-40-00 | Phase 2 | Recruiting | 377 | Primary endpoint not disclosed in English source |
| NCT05968326 | Phase 2 | Active, not recruiting | 260 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced Melanoma
Phase 2; n=131; evaluation: Not stated in English source. Reported fields: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v.1.1) After Randomization(Median) = 7.9 Month (95%CI, 2.8 - 22.7); Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v.1.1) After Randomization(Median) = 8.3 Month (95%CI, 6.9 - 26.9)
954P - A randomized phase II study of autogene cevumeran plus pembrolizumab (pembro) versus pembro in 1L advanced melanoma (IMcode001)
Phase 2; n=125; evaluation: Negative. Reported fields: mPFS = 8.3 Month ; mPFS = 7.9 Month
Clinical result record from source dataset
Not disclosed; n=not disclosed; evaluation: Not stated in English source. Reported fields: Detailed result fields not available in English
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Autogene cevumeran addresses Muscle Invasive Bladder Urothelial Carcinoma, Pancreatic Ductal Adenocarcinoma, Unresectable Acral Lentiginous Melanoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Personalized antigen vaccine, mRNA vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2016-09-21 | BioNTech to enter into worldwide strategic collaboration with Genentech to develop individualized mRNA cancer therapies | BioNTech | Not disclosed | US$310.0M upfront |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Methods of treating urothelial carcinoma with a PD-1 axis binding antagonist and an RNA vaccine”. The milestone feed surfaced a patent-application signal described as “Systems and methods for producing pharmaceutical compositions using peristaltic pumps and dampeners”. The milestone feed surfaced a patent-application signal described as “Methods of inducing neoepitope-specific t cells with a PD-1 axis binding antagonist and an RNA vaccine”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Immunogenicity durability and clinically meaningful protection
- Population selection, endpoint timing, and comparator relevance
- Manufacturing consistency, distribution, and uptake
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-16. Counts and status fields may change as source records update.
